Jennifer Bush Sells 8,790 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) COO Jennifer Bush sold 8,790 shares of the business’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total transaction of $79,197.90. Following the completion of the sale, the chief operating officer owned 337,920 shares in the company, valued at approximately $3,044,659.20. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Trading Down 8.3%

Shares of ARTV opened at $7.84 on Thursday. The firm has a market cap of $193.80 million, a P/E ratio of -2.21 and a beta of 2.86. The company’s 50-day moving average price is $8.36 and its 200 day moving average price is $5.67. Artiva Biotherapeutics, Inc. has a 12-month low of $1.47 and a 12-month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Equities research analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Artiva Biotherapeutics News Roundup

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Artiva announced multiple AlloNK® data presentations for the upcoming EULAR 2026 Congress, including a late-breaking oral presentation highlighting clinical efficacy comparable to autologous CAR T-cell therapy in rheumatologic diseases. Article Title
• Positive Sentiment: The company appointed veteran biotech executive Diego Miralles, M.D., as President and Head of Research and Development, which could strengthen leadership and development execution. Article Title
• Neutral Sentiment: Artiva disclosed several insider sales by CEO Fred Aslan, COO Jennifer Bush, SVP Heather Raymon, and insider Christopher Horan/ Subhashis Banerjee at $9.01 per share; the company said these were primarily for tax withholding related to equity vesting, which makes them less alarming than open-market selling. Article Title
• Neutral Sentiment: Recent analyst commentary remains constructive overall, with multiple firms raising price targets sharply, but the stock also faces skepticism from some ratings changes and a still-loss-making earnings profile.
• Negative Sentiment: The company recently reported a quarterly loss of $0.95 per share, wider than expectations, reinforcing concerns about ongoing losses and execution risk.

Wall Street Analyst Weigh In

ARTV has been the topic of a number of recent research reports. Wall Street Zen lowered shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Cantor Fitzgerald boosted their price target on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Needham & Company LLC boosted their price target on shares of Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. HC Wainwright boosted their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ARTV. Citadel Advisors LLC grew its position in shares of Artiva Biotherapeutics by 419.3% during the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after buying an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after purchasing an additional 117,733 shares in the last quarter. Marshall Wace LLP acquired a new position in Artiva Biotherapeutics in the fourth quarter valued at approximately $341,000. Jane Street Group LLC acquired a new position in Artiva Biotherapeutics in the second quarter valued at approximately $67,000. Finally, Landscape Capital Management L.L.C. acquired a new position in Artiva Biotherapeutics in the third quarter valued at approximately $112,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.